Unlocking Insights
in ATTR-CM
Diagnostic challenge
As there is no specific ICD-10 marker code for aTTR-CM, diagnosis requires both amyloidosis (identified by E85. ICD-10 code or a tafamidis meglumine delivery) and a cardiovascular condition (identified by ICD-10 or medical procedure codes related to either heart failure, arrhythmias, conduction disorders or cardiomyopathies), which are not necessarily reported at the same visit.
New insights
The prevalence data of aTTR-CM is limited and not well characterized, due to missed and delayed diagnosis in most patients, its heterogenous clinical presentation, and previously lacking sensitive diagnostic modality. The emergence of effective therapies for patients with amyloid transthyretin (ATTR) amyloidosis, and specifically cardiac ATTR amyloidosis, is a relatively recent and exciting development.
Unpacking The Data
The Sources Behind Our Insights
Unlock Research Questions
Our dataset° offers life science companies unparalleled insights into the relationship between specific biomarkers, comorbidities, and treatment outcomes in ATTR-CM.
Research Question/ Endpoints
Demographics
Comorbidities
Lab results & echocardiography
Hospital visits & admissions
Survival
Biomarkers, genetic drivers
Hospital visit & admissions
Survival
Biomarkers, Genetic drivers
Outcomes
Adverse events
Complications
Titration / Dosing
Treatment dynamics
Incidence & Prevalence
Adherence
Efficacy
Indication split
Safety profile
How Pharma Can Leverage LynxCare's Dataset
Clinical Trial Design
Our granular and quality-controlled real-world dataset can help design clinical trials that better reflect real-world scenarios.
Synthetic Control Arm
Our dataset can be used to create synthetic control arms, which can be used to evaluate the effectiveness of new treatments.
Market Access
Our dataset can help pharma companies gain a better understanding of the market and generate granular value dossiers for HEOR.
Medical Affairs
Our dataset can help medical affairs teams better understand the clinical outcomes and real-world evidence associated with their products.
How Hospitals Can Benefit from a LynxCare Database
Improving Patient Care
Find more relevant medical information thanks to LynxCare's disease-specific NLP pipeline for a better patient and population understanding.
Research & Network Opportunities
Initiate or participate in national and international multi-center, multi-country RWE studies.
Benefit from network of KOLs.
Scientific Research
Initiate or participate in (pharma- or physician initiated) peer-reviewed (multi-center, multi-country) publications
Increased Clinical Trial Participation
More effective patients/cohort selection through clinical NLP, enrolling more patients in clinical trials
Improve your Data Quality
Receive feedback on the clinical data quality of your hospital’s database.
Benefit from data science training provided
World-Class Expertise.
The LynxCare Advantage
Differentiating factors from other NLP providers & established RWD vendors
Building Trust
Quality Control and Data Freshness
Quality Control
Data Freshness
OMOP CDM Data Warehouse
Patient Insights
More Than Numbers
Individualized Care
Cross-Disciplinary Collaboration
Impact on Patient Outcomes
The Future of ATTR-CM Treatment
How LynxCare Can Help
Personalized Medicine
By providing insights into individual pathways of ATTR-CM patients, our data asset enables clinicians to tailor treatments to specific patient needs, opening up the possibility of personalized medicine.
Improved Outcomes
By providing insights into the clinical pathway of patients diagnosed with aTTR-CM, our data asset aims to ultimately improve patient outcomes by providing valuable insights for clinicians and researchers.
Continued Innovation
With our comprehensive dataset and world-class expertise, we aim to continue to drive innovation in the treatment and management of aTTR-CM patients, ensuring that the latest insights and solutions are available to healthcare providers and researchers.
° LynxCare datasets concern datasets within the LynxCare's European hospital network. The hospitals are the data controllers. No commitment before site approval on RWE request.
